Amgen (NASDAQ:AMGN) Price Target Raised to $327.00 at Truist Financial

Amgen (NASDAQ:AMGN) had its target price upped by equities research analysts at Truist Financial from $325.00 to $327.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the medical research company’s stock. Truist Financial’s price objective would indicate a potential downside of 0.43% from the stock’s previous close.

A number of other analysts have also recently issued reports on AMGN. TD Cowen reiterated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. Barclays began coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price on the stock. Wells Fargo & Company increased their price target on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Finally, The Goldman Sachs Group boosted their price objective on Amgen from $415.00 to $425.00 and gave the stock a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $357.54.

Amgen Trading Down 5.1%

Amgen stock traded down $17.83 during trading on Friday, reaching $328.42. The company had a trading volume of 2,281,955 shares, compared to its average volume of 2,726,078. Amgen has a 12-month low of $261.43 and a 12-month high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock’s 50 day moving average price is $358.07 and its two-hundred day moving average price is $340.45. The firm has a market capitalization of $177.24 billion, a price-to-earnings ratio of 23.07, a PEG ratio of 3.34 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.73 by $0.42. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter last year, the firm posted $4.90 earnings per share. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts expect that Amgen will post 22.16 earnings per share for the current fiscal year.

Institutional Trading of Amgen

Several large investors have recently modified their holdings of the business. Norges Bank purchased a new position in Amgen in the fourth quarter valued at about $2,164,162,000. Capital World Investors grew its position in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. State Street Corp increased its stake in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares during the last quarter. Geode Capital Management LLC raised its holdings in Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after acquiring an additional 1,035,779 shares in the last quarter. Finally, Amundi boosted its stake in Amgen by 41.1% during the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock valued at $1,111,854,000 after acquiring an additional 988,856 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 beats and raised full-year outlook — Amgen reported Q1 EPS of $5.15 (vs. $4.73 est.) and revenue of $8.62B, and issued FY2026 EPS guidance of $21.70–$23.10, which supports longer?term earnings visibility. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Broad product momentum — Management highlighted 16 drugs with double?digit growth and +4% product sales, showing portfolio resilience versus biosimilar erosion and legacy pressures. Zacks: 16 Drugs Deliver Double-Digit Gains
• Positive Sentiment: Analyst bullishness and higher price target — Goldman Sachs raised its AMGN price target to $425 and maintained a Buy; other analysts reiterated Buys, underpinning upside expectations. Goldman Sachs Raises Price Target to $425
• Neutral Sentiment: Pipeline focus — Management emphasized an expanded MariTide (obesity) development program as a multi?year growth driver; concrete near-term revenue impact is uncertain and will depend on clinical progress and regulatory timelines. Reuters: Sales Rise 4%; MariTide Program
• Neutral Sentiment: Earnings materials and calls available — Full Q1 transcript, slides and call recording provide more detail for investors to model product-level growth and guidance assumptions. Earnings Call Transcript
• Negative Sentiment: FDA proposal to withdraw Tavneos — The FDA has proposed withdrawing Tavneos approval citing alleged clinical?trial data manipulation and untrue statements, raising regulatory, legal and reputational risks that could pressure the stock. FDA Tavneos Proposal
• Negative Sentiment: Investor caution on execution and strategy — Some coverage noted the report was “generally in?line” (not a clear blowout) and that the company’s aggressive push into obesity and other areas adds near?term execution risk; that tone contributed to selling pressure. Amgen Aggressively Expanding in Obesity
• Negative Sentiment: Market impact headline — Broad-market stories noted Amgen was a drag on the Dow amid mixed macro/earnings headlines, which can amplify intraday declines in large-cap pharma names. Nasdaq Leads as Amgen Drags Dow

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.